Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143325 · ClinicalTrials.gov registry record · Phase 3
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
A Phase 3 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT00143325 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 730 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00143325, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
Conditions Studied
Interventions
- DRUG varenicline (CP-526,555)
Study Locations (20)
Other
- Pfizer Investigational Site - Brussels
- Pfizer Investigational Site - Edegem
- Pfizer Investigational Site - Ghent
- Pfizer Investigational Site - Caen
- Pfizer Investigational Site - Clermont-Ferrand
- Pfizer Investigational Site - Limeil-Brévannes
- Pfizer Investigational Site - Metz
- Pfizer Investigational Site - Paris
- Pfizer Investigational Site - Vandœuvre-lès-Nancy
- Pfizer Investigational Site - Amsterdam
- Pfizer Investigational Site - Enschede
- Pfizer Investigational Site - Maastricht
- Pfizer Investigational Site - Zutphen
California
- Pfizer Investigational Site - Palo Alto
- Pfizer Investigational Site - Santa Ana
Connecticut
- Pfizer Investigational Site - Farmington
Kentucky
- Pfizer Investigational Site - Lexington
Massachusetts
- Pfizer Investigational Site - Worcester
Oregon
- Pfizer Investigational Site - Portland
Surrey
- Pfizer Investigational Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143325
The ClinicalTrials.gov registry entry for NCT00143325 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (55% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which varenicline (CP-526,555) is the first listed.
NCT00143325 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00143325 about?
NCT00143325 is a clinical study titled "An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation". Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
What is the current status of trial NCT00143325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2005-01. Estimated completion is 2006-06.
What conditions does trial NCT00143325 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00143325?
The interventions under investigation include: varenicline (CP-526,555) (DRUG).
Who is sponsoring clinical trial NCT00143325?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00143325 being conducted?
This trial has 20 study locations across California, Connecticut, Kentucky, Massachusetts, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.